A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B.

Abstract

BACKGROUND:

Emtricitabine is a nucleoside analogue approved for treatment of human immunodeficiency virus 1 with clinical activity against hepatitis B virus (HBV).

METHODS:

To compare the safety and efficacy of emtricitabine with placebo in patients with HBV, we conducted a randomized (2:1), double-blind study at 34 sites in North America, Asia, and Europe that enrolled adults between November 2000 and July 2002 who had chronic HBV infection but had never been exposed to nucleoside or nucleotide treatment. Each patient received either 200 mg of emtricitabine (n=167) or placebo (n=81) once daily for 48 weeks and underwent a pretreatment and end-of-treatment liver biopsy. Histologic improvement was defined as a 2-point reduction in Knodell necroinflammatory score with no worsening in fibrosis.

RESULTS:

At the end of treatment, 103 (62%) of 167 patients receiving active treatment had improved liver histologic findings vs 20 (25%) of 81 receiving placebo (P<.001), with significance demonstrated in subgroups positive (P<.001) and negative (P=.002) for hepatitis Be (HBe) antigen. Serum HBV DNA readings showed less than 400 copies/mL in 91 (54%) of 167 patients in the emtricitabine group vs 2 (2%) of 81 in the placebo group (P<.001); alanine aminotransferase levels were normal in 65% (109/167) vs 25% (20/81), respectively (P<.001). At week 48, 20 (13%) of 159 patients in the emtricitabine group with HBV DNA measured at the end of treatment had detectable virus with resistance mutations (95% confidence interval, 8%-18%). The rate of seroconversion to anti-HBe (12%) and HBe antigen loss were not different between arms. The safety profile of emtricitabine during treatment was similar to that of placebo. Posttreatment exacerbation of HBV infection developed in 23% of emtricitabine-treated patients.

CONCLUSION:

In patients with chronic HBV, both positive and negative for HBe antigen, 48 weeks of emtricitabine treatment resulted in significant histologic, virologic, and biochemical improvement.

• Authors: Seng Gee Lim, Tay Meng Ng, Nelson Kung, Zahary Krastev, Miroslava Volfova, Petr Husa, Samuel S Lee, Sing Chan, Mitchell L Shiffman, Mary Kay Washington, Amy Rigney, Jane Anderson, Elsa Mondou, Andrea Snow, Jeff Sorbel, Richard Guan, Franck Rousseau, Emtricitabine FTCB-301 Study Group
• Journal: Archives of internal medicine (Arch Intern Med) Vol. 166 Issue 1 Pg. 49-56 (Jan 09 2006) ISSN: 0003-9926 [Print] United States
• PMID: 16401810 (Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Antiviral Agents
• DNA, Viral
• Hepatitis B Antibodies
• Deoxycytidine
• Alanine Transaminase
• Emtricitabine

Topics

• Adult
• Aged
• Alanine Transaminase (blood)
• Antiviral Agents (therapeutic use)
• Biopsy, Needle
• DNA, Viral (blood)
• Deoxycytidine (analogs & derivatives, therapeutic use)
• Double-Blind Method
• Emtricitabine
• Female
• Genotype
• Hepatitis B Antibodies (blood)
• Hepatitis B virus (drug effects, isolation & purification)
• Hepatitis B, Chronic (diagnosis, drug therapy, physiopathology)
• Humans
• Liver (pathology, virology)
• Male
• Middle Aged
• Placebo Effect
• Treatment Outcome
• Viral Load